Latigo Biotherapeutics Files for Nasdaq IPO, Aims to Raise Up to $288 Million

Latigo Biotherapeutics has filed for an initial public offering, aiming to raise as much as $288 million as it prepares to list on the Nasdaq exchange. The plans were detailed in a regulatory filing, marking the company's move to enter the public markets.

Offering Details

According to the filing, Latigo intends to offer 16,000,000 shares of its common stock to the public. The company has set an anticipated price range of $16.00 to $18.00 per share.

Latigo Biotherapeutics has applied to list its stock on the Nasdaq Global Select Market under the proposed ticker symbol LTGO. The filing notes that there has been no public market for its common stock prior to this offering.

Ad

Financial Implications

At the top end of the stated price range, the IPO would generate gross proceeds of $288 million before underwriting discounts and commissions. The final amount raised will depend on investor demand and where the offering is ultimately priced.

For a clinical-stage biopharmaceutical company, a successful IPO provides critical capital to fund research and development, advance product candidates through clinical trials, and cover operational expenses. The performance of the offering will be closely watched as an indicator of investor appetite for developmental-stage biotech firms.